Relmada Therapeutics, INC 8-K filings

Relmada Therapeutics announced its second quarter 2026 financial results, highlighting progress in advancing NDV-01 and sepranolone toward IND filings by year-end 2026, supported by a robust cash balance extending operations through 2029.

Relmada Therapeutics announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer to lead corporate strategy and business development.

Relmada Therapeutics stockholders approved an increase in authorized common stock to 200 million shares at the 2026 Annual Meeting.

Relmada Therapeutics announced positive 12-month Phase 2 data for NDV-01 in bladder cancer, a $160 million PIPE financing, and plans to initiate Phase 3 trials in mid-2026.

Relmada Therapeutics, Inc. announced amended employment agreements for its executive officers, including salary increases and revised severance packages, effective January 1, 2026.

Relmada Therapeutics announced its third-quarter 2025 financial results, highlighted by positive 9-month data for its NDV-01 bladder cancer therapy and FDA alignment on Phase 3 trial designs, alongside a $100 million capital raise.

Relmada Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expected to raise approximately $100 million in gross proceeds.

Relmada Therapeutics announced positive FDA feedback for two Phase 3 registrational paths for NDV-01 in NMIBC and reported strong 9-month safety and efficacy data from its Phase 2 study.

Relmada Therapeutics, Inc. updated its corporate presentation, showcasing positive Phase 2 data for NDV-01 in NMIBC and outlining key development milestones for both NDV-01 and sepranolone through H1 2026.

Relmada Therapeutics announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Relmada Therapeutics provides a mid-year update, highlighting strong Phase 2 NDV-01 data and plans for Phase 3, alongside progress for Sepranolone in Prader-Willi Syndrome.

Relmada Therapeutics' Chief Medical Officer-Urology, Dr. Raj S. Pruthi, purchased 55,000 shares of company common stock in open market transactions.

Relmada Therapeutics announced positive 6-month follow-up data for its NDV-01 bladder cancer therapy, alongside narrowed Q2 2025 net loss and plans for Phase 3 initiation.

Relmada Therapeutics, Inc. announced its transfer to the Nasdaq Capital Market and received a 180-day extension to regain compliance with the $1 minimum bid price requirement.

Relmada Therapeutics, Inc. has formally terminated its 2018 License Agreement with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi, ending its esmethadone development program.

Relmada Therapeutics, Inc. announced the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Urology to spearhead the development of its lead non-muscle invasive bladder cancer (NMIBC) program, NDV-01, with a Phase 3 trial expected to commence in H1 2026.

Relmada Therapeutics, Inc. announced that its stockholders approved the election of a Class I director, ratified the appointment of independent auditors, and authorized an increase in shares for its equity incentive plan at the 2025 Annual Meeting.

Relmada Therapeutics dismisses Marcum LLP as its independent auditor due to its acquisition by CBIZ CPAs, and subsequently engages CBIZ CPAs as its new auditor.

Relmada Therapeutics reports promising initial Phase 2 data for NDV-01, showing a 90% high-grade disease-free status in patients with non-muscle invasive bladder cancer (NMIBC).

Relmada Therapeutics reports its Q4 and full year 2024 financial results, highlighting progress with NDV-01 and sepranolone programs and a cash balance of $44.8 million.

Relmada Therapeutics acquires exclusive rights to NDV-01, a novel bladder cancer treatment, from Trigone Pharma, expanding its pipeline.

Relmada Therapeutics expands its CNS portfolio by acquiring Sepranolone, a Phase 2b ready asset, from Asarina Pharma AB for the treatment of Tourette Syndrome and other compulsive disorders.

Relmada Therapeutics has received a notification from Nasdaq that its stock price has fallen below the required minimum of $1 per share, placing it at risk of delisting.

Relmada Therapeutics has appointed Paul Kelly as Chief Operating Officer, effective January 1, 2025, and amended employment agreements for its other top executives.

Relmada Therapeutics has discontinued its Reliance II and Relight Phase 3 studies for REL-1017 following a data review and is exploring strategic options to maximize shareholder value.

Relmada Therapeutics announced that its Phase 3 Reliance II trial for REL-1017 as an adjunctive treatment for major depressive disorder is unlikely to meet its primary efficacy endpoint based on an interim analysis.

Relmada Therapeutics held its 2024 Annual Meeting of Stockholders, where directors were elected, auditors were ratified, and proposals regarding equity incentive plans and executive compensation were voted on.

Relmada Therapeutics announced a corporate update and preliminary financial results for the fourth quarter and full year 2023, highlighting progress in their Phase 3 clinical trials for REL-1017 and the initiation of a Phase 1 trial for their psilocybin program.

Relmada Therapeutics has finalized a separation agreement with its former Chief Medical Officer, Dr. Cedric OGorman, including a payment of $414,500 and six months of COBRA premium coverage.